Regeneron Pharmaceuticals (REGN) Income from Continuing Operations (2009 - 2026)
Regeneron Pharmaceuticals' quarterly Income from Continuing Operations came in at 727200000.0 in Q1 2026, down 10.08% year-on-year from 808700000.0 in Q1 2025, and down 13.9% quarter-over-quarter from 844600000.0 in Q4 2025.
Regeneron Pharmaceuticals has reported Income from Continuing Operations for 18 years, with the latest figure at 727200000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 10.08% year-over-year to 727200000.0; the trailing twelve-month figure through Mar 2026 stood at 4423400000.0 (down 1.69% YoY), and the FY2025 full-year result was 4504900000.0, up 2.09% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 727200000.0, down from 844600000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1460000000.0 in Q3 2025, with the low at 722000000.0 in Q1 2024.
- Average Income from Continuing Operations over 5 years is 1055100000.0, with a median of 973500000.0 recorded in 2022.
- Year-over-year, Income from Continuing Operations slumped 72.5% in 2022 and surged 47.9% in 2024.
- Tracing REGN's Income from Continuing Operations over 5 years: stood at 1197100000.0 in 2022, then decreased by 3.13% to 1159600000.0 in 2023, then slipped by 20.86% to 917700000.0 in 2024, then declined by 7.97% to 844600000.0 in 2025, then decreased by 13.9% to 727200000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 727200000.0 (Q1 2026), 844600000.0 (Q4 2025), and 1460000000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 727.20 Mn |
| Dec 31, 2025 | 844.60 Mn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Mar 31, 2025 | 808.70 Mn |
| Dec 31, 2024 | 917.70 Mn |
| Sep 30, 2024 | 1.34 Bn |
| Jun 30, 2024 | 1.43 Bn |
| Mar 31, 2024 | 722.00 Mn |
| Dec 31, 2023 | 1.16 Bn |
| Sep 30, 2023 | 1.01 Bn |
| Jun 30, 2023 | 968.40 Mn |
| Mar 31, 2023 | 817.80 Mn |
| Dec 31, 2022 | 1.20 Bn |
| Sep 30, 2022 | 1.32 Bn |
| Jun 30, 2022 | 852.10 Mn |
| Mar 31, 2022 | 973.50 Mn |
| Dec 31, 2021 | 2.23 Bn |
| Sep 30, 2021 | 1.63 Bn |
| Jun 30, 2021 | 3.10 Bn |
| Mar 31, 2021 | 1.12 Bn |
| Dec 31, 2020 | 1.15 Bn |
| Sep 30, 2020 | 842.10 Mn |
| Jun 30, 2020 | 897.30 Mn |
| Mar 31, 2020 | 624.60 Mn |
| Dec 31, 2019 | 792.00 Mn |
| Sep 30, 2019 | 669.60 Mn |
| Jun 30, 2019 | 193.10 Mn |
| Mar 31, 2019 | 461.10 Mn |
| Dec 31, 2018 | 820.40 Mn |
| Sep 30, 2018 | 594.70 Mn |
| Jun 30, 2018 | 551.40 Mn |
| Mar 31, 2018 | 478.00 Mn |
| Dec 31, 2017 | 173.51 Mn |
| Sep 30, 2017 | 388.32 Mn |
| Jun 30, 2017 | 387.74 Mn |
| Mar 31, 2017 | 248.93 Mn |
| Dec 31, 2016 | 253.09 Mn |
| Sep 30, 2016 | 264.80 Mn |
| Jun 30, 2016 | 196.22 Mn |
| Mar 31, 2016 | 181.39 Mn |
| Dec 31, 2015 | 154.99 Mn |
| Sep 30, 2015 | 210.40 Mn |
| Jun 30, 2015 | 194.64 Mn |
| Mar 31, 2015 | 76.02 Mn |
| Dec 31, 2014 | -142.68 Mn |
| Sep 30, 2014 | 83.38 Mn |
| Jun 30, 2014 | 96.35 Mn |
| Mar 31, 2014 | 68.31 Mn |
| Dec 31, 2013 | 86.18 Mn |
| Sep 30, 2013 | 141.31 Mn |
| Jun 30, 2013 | 87.38 Mn |
| Mar 31, 2013 | 98.87 Mn |
| Dec 31, 2012 | 470.36 Mn |
| Sep 30, 2012 | 191.47 Mn |
| Jun 30, 2012 | 76.74 Mn |
| Mar 31, 2012 | 11.65 Mn |
| Dec 31, 2011 | -53.44 Mn |
| Sep 30, 2011 | -62.37 Mn |
| Jun 30, 2011 | -62.51 Mn |
| Mar 31, 2011 | -43.45 Mn |
| Dec 31, 2010 | -14.60 Mn |
| Sep 30, 2010 | -33.88 Mn |
| Jun 30, 2010 | -25.47 Mn |
| Mar 31, 2010 | -30.52 Mn |
| Dec 31, 2009 | -40.61 Mn |
| Sep 30, 2009 | -1.02 Mn |
| Jun 30, 2009 | -14.94 Mn |